Geron Appoints Graham Cooper as CFO
Geron, a biopharmaceutical company developing cancer therapeutics, has appointed Graham Cooper as executive vice president (EVP), finance and business development and chief financial officer (CFO). Cooper will provide direction for all financial matters for Geron and be responsible for new business opportunities and investor relations for the company.
From 2006 until 2011, Cooper served as senior vice president (SVP), CFO and treasurer of Orexigen Therapeutics. He was instrumental in growing Orexigen from a venture-backed start-up into a sizeable public company, completing a large Phase 3 obesity programme and filing an non-disclosure agreement (NDA) with the Food and Drug Administration (FDA).
Previously, Cooper held the position of director, healthcare investment banking at Deutsche Bank Securities, where for over eight years he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field.
Cooper has earned a certified public accountant (CPA) and holds a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.